New Funding Opportunity: Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices (BAA) NIH-BAA-75N93021R00019

Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases          Visit us on the Web The NIAID Radiation and Nuclear Countermeasures Program (RNCP) supports extramural research to develop safe and effective radiation medical countermeasures and biodosimetry assays/devices for use during a radiation public health emergency. We are pleased to present the following new funding opportunity: Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices (BAA, Clinical Trial Not Allowed) NIH-BAA-75N93021R00019 Currently, there are four medical countermeasures (MCMs) approved by the Food and Drug Administration (FDA) for treatment of hematopoietic (H) acute radiation syndrome (ARS). However, there are no approved MCMs for other radiation subsyndromes (gut, skin, lung, heart, kidney, etc.), and no biodosimetry test has yet been FDA cleared. This initiative will support the research and development of MCMs for ARS and/or the delayed effects of acute radiation exposure (DEARE) or biodosimetry approaches to assess radiation exposure level. Specific research interests include MCMs for radiation syndromes other than H-ARS (or H-ARS MCMs that are effective when administered 48 hours or later post-irradiation); or biodosimetry approaches. Through this initiative, the NIAID RNCP will support research and development studies that are anticipated to advance MCMs or biodosimetry approaches toward submission of an Investigational New Drug (IND) or Investigational Use Only (IUO) application and eventual approval/licensure/clearance from the FDA. Applications are due April 15, 2022, by 3 p.m. Eastern Time. Please address inquiries to the NIAID Contracting Officer for this BAA: Anuj Patel anuj.patel@nih.gov 240-669-5142 Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107